Vamorolone

Vamorolone (VBP15) is a first-in-class, orally active dissociative steroidal anti-inflammatory agent and membrane-stabilizer. Vamorolone improves muscular dystrophy without side effects. Vamorolone shows potent NF-κB inhibition and substantially reduces hormonal effects[1][2].

Product Specifications

CAS Number

[13209-41-1]

Product Name Alternative

VBP15

UNSPSC

12352211

Hazard Statement

H302, H315, H319, H335

Target

Glucocorticoid Receptor; Mineralocorticoid Receptor; NF-κB

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Vitamin D Related/Nuclear Receptor

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/vamorolone.html

Purity

99.48

Solubility

DMSO : 62.5 mg/mL (ultrasonic)

Smiles

C[C@@]12[C@](C(CO)=O)(O)[C@H](C)C[C@@]1([H])[C@]3([H])CCC4=CC(C=C[C@]4(C)C3=CC2)=O

Molecular Formula

C22H28O4

Molecular Weight

356.46

Precautions

H302, H315, H319, H335

References & Citations

[1]Heier CR, et al. VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med. 2013 Oct;5 (10) :1569-85.|[2]Dillingham BC, et al. VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis. Cell Mol Neurobiol. 2015 Apr;35 (3) :377-387.|[3]Heier CR, et al. Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. Life Sci Alliance. 2019 Feb 11;2 (1) . pii: e201800186.